Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Kriya Therapeutics.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Kriya Therapeutics
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
3000 El Camino Real, Building 4, Suite 200 Palo Alto, CA 94306
Telephone
Telephone
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The collaboration aims to advance Kriya’s portfolio of gene therapies designed to block complement C3 and C5 for retinal diseases using Everads' suprachoroidal delivery device.


Lead Product(s): AAV Gene Therapy

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Everads Therapy

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 27, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Kriya acquires a portfolio of Fibroblast Growth Factor 21 (FGF21) assets including Tramontane’s lead program, an adeno-associated virus (AAV) vector designed to express a steady level of the native FGF21 protein, for treating people with NASH.


Lead Product(s): AAV Gene Therapy

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Tramontane Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition September 06, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The net proceeds from the financing will support the clinical translation of Kriya’s broad pipeline of gene therapies and continued scaling of its engineering, computational and manufacturing platforms.


Lead Product(s): Gene Therapy

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Patient Square Capital

Deal Size: $430.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing July 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN).


Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy

Recipient: Redpin Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Proceeds from this financing will support the advancement of Kriya’s pipeline and continued scaling of its engineering, manufacturing, and computational platforms. Kriya has established an ecosystem for delivering best-in-class technologies and medicines in gene therapy.


Lead Product(s): Undisclosed

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Patient Square Capital

Deal Size: $270.0 million Upfront Cash: Undisclosed

Deal Type: Series C Financing May 16, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Twist Biopharma, expects to leverage its antibody discovery and optimization platform to discover novel antibodies against specific targets of interest that will be engineered into Kriya’s proprietary gene therapy technology platform for durable and targeted delivery.


Lead Product(s): Antibody,AAV-based Gene Therapy

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Large molecule

Partner/Sponsor/Collaborator: Twist Bioscience

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement March 09, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through this agreement, Kriya is advancing gene therapies that are designed to durably express engineered molecules that selectively reduce complement hyperactivity at the site of pathology following one-time administration.


Lead Product(s): Undisclosed

Therapeutic Area: Ophthalmology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Medical University of South Carolina

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 26, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Kriya has obtained exclusive rights to Warden Bio’s five preclinical gene therapy programs. This acquisition serves as the foundation for Kriya’s Rare Disease Division focused on the discovery and development of gene therapies for rare diseases.


Lead Product(s): AAV-mediated Gene Therapy

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy

Recipient: Warden Bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Financing proceeds will support the development of Kriya's pipeline, internal discovery engine, and proprietary GMP manufacturing infrastructure. Kriya's initial pipeline includes multiple AAV-based gene therapies for the treatment of metabolic diseases.


Lead Product(s): KT-A112

Therapeutic Area: Endocrinology Product Name: Undisclosed

Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: QVT

Deal Size: $80.5 million Upfront Cash: Undisclosed

Deal Type: Series A Financing May 12, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY